{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:31:25Z","timestamp":1792211485631,"version":"4.4.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Drug-induced sarcoidosis-like reaction (DISR) is a rare adverse event associated with immunotherapy. Currently, there is no standardized treatment protocol for DISR linked to immune checkpoint inhibitors (ICIs). This study presents a case of an early-stage triple-negative breast cancer (TNBC) patient who developed hepatic sarcoidosis-like reactions during neoadjuvant pembrolizumab therapy. We provide an overview of ICI-induced sarcoidosis-like reactions in cancer patients, including incidence, mechanisms, clinical manifestations, treatment, and prognosis. Additionally, we discuss the significance of one-year adjuvant immunotherapy for early-stage TNBC patients who achieved pathological complete response after neoadjuvant therapy, offering insights for individualized therapeutic strategies in this population.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1589191","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:41:22Z","timestamp":1750225282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yujing","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"OP2400371","DOI":"10.1200\/OP.24.00371","article-title":"Real-world immune-related adverse events in patients with early triple-negative breast cancer who received pembrolizumab","volume":"2024","author":"Jayan","year":"2004","journal-title":"JCO Oncol Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2022.09.127","article-title":"Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy","volume":"78","author":"Li","year":"2023","journal-title":"Clin Radiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2024.2342222","article-title":"Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations","volume":"16","author":"Rizzo","year":"2024","journal-title":"Immunotherapy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02546-w","article-title":"Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital","volume":"23","author":"Torres-Jimenez","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/medicina59050991","article-title":"Renal sarcoidosis-like reaction induced by PD-1 inhibitor treatment in non-small cell lung cancer: A case report and literature review","volume":"59","author":"Park","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203621","article-title":"Hilar\/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report","volume":"14","author":"Sagawa","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034432","article-title":"Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report","volume":"102","author":"Li","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2709062","DOI":"10.1155\/2022\/2709062","article-title":"Atezolizumab-induced sarcoidosis-like reaction in a patient with metastatic breast cancer","volume":"2022","author":"Tsunoda","year":"2022","journal-title":"Case Rep Oncol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14228","article-title":"Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response","volume":"12","author":"Shi","year":"2021","journal-title":"Thorac Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:41:24Z","timestamp":1750225284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2025.1589191"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1589191","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1589191"}}